HUGE News and Press, FSD Pharma Inc. From 04/02/24

2024-04-02 06:00:31 ET More on FSD Pharma Financial information for FSD Pharma Read the full article on Seeking Alpha For further details see: FSD Pharma GAAP EPS of -$0.46

TORONTO, ON / ACCESSWIRE / April 1, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today a...

China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...

2024-03-27 17:08:02 ET The FDA approved FSD Pharma to submit an Investigational New Drug (I.N.D.) application FSD Pharma is a specialty biotech pharmaceutical company. FSD Pharma BioSciences, Inc., is a wholly-owned subsidiary. Moreover, it is a specialty biotech pharmaceutical R&...

2024-03-27 17:08:02 ET Drug with properties to reduce chronic inflammation FSD Pharma is a specialty biotech pharmaceutical R&D company. FSD Pharma BioSciences, a wholly-owned subsidiary, is focusing on developing multiple applications of the company’s lead compound FSD...

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, through its subsidiary, HUGE Biopharma Australia Pty Ltd., entered into agreement with iNG...

TORONTO, ON / ACCESSWIRE / March 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today anno...

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical Trial Application (“CTA”) for its planned phase-1b ...

TORONTO, ON / ACCESSWIRE / March 11, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (" FSD Pharma " or the " Company "), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today anno...

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 For...